SCHEMBL5557461

SCHEMBL5557461

CC(C)(C)OC(=O)Nc1ccc(C(F)(F)F)cc1NC(=O)CC(=O)c1cccc(-c2ccncc2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CCR2 P41597 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
AAK1 Q2M2I8 2/20 0.41
RXRA P19793 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
BRAF P15056 1/20 0.39
P2RY14 Q15391 1/20 0.38
DGAT2 Q96PD7 1/20 0.38
MAP2K4 P45985 1/20 0.38
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5563428 0.91 MEN1 (0.44) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5556638 0.91 MEN1 (0.44) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5559202 0.89 CCR2 (0.46) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5557524 0.89 CYP17A1 (0.50) CYP17A1KMT2AAAK1
SCHEMBL5563946 0.89 MEN1 (0.42) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5556906 0.89 KMT2A (0.43) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5563087 0.88 ALDH1A1 (0.47) MEN1KMT2AALDH1A1CCR2RXFP1
SCHEMBL5557676 0.88 CCR2 (0.43) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5558688 0.88 MEN1 (0.41) CYP17A1MEN1KMT2AALDH1A1CCR2
SCHEMBL5563263 0.88 CYP17A1 (0.44) CYP17A1RXFP1AAK1RXRANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
EP-1651234-B1 COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 CYP17A1 942/4885MEN1 1739/4885KMT2A 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.